Posted by Michael Wonder on 01 Sep 2019
ICER posts draft scoping document for the assessment of treatments for sickle cell disease
30 August 2019 - Document open to public comment until 20 September 2019.
The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document outlining a planned review of the comparative clinical effectiveness and value treatments for crizanlizumab and voxelotor, both of which will be indicated for sickle cell disease.
Crizanlizumab, a P-selectin inhibitor, is currently under FDA priority review with an anticipated decision expected in the first half of 2020. Global Blood Therapeutics is planning to initiate and complete a rolling NDA for voxelotor, an HbS polymerization inhibitor, before the end of 2019.
